Summary
48 / 100 · Bulios Score
What speaks for it
- It earns 21 GBP a year on every 100 GBP of invested capital.
- It could repay all its net debt from 1.8 years of operating profit.
What to watch
- It pays out more in dividends than it earns: 281% of profit.
- The share price is above the Bulios Fair Price.
- Revenue fell by 3.7% a year over the last 3 years.
- Out of every 100 GBP of revenue, only 0.7 GBP is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 152.8 GBP for 1 GBP of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue fell by 20% a year over 5 years. Over the last 3 years it fell by 3.7% a year. For the next fiscal year analysts expect revenue to grow by 6.6%.
Growth in detailDoes it make money?
ReasonablyWhere 100 GBP of revenue goes
- Cost of sales 53 GBP
- Sales and administration 40 GBP
- Taxes and other 6.0 GBP
- Net profit 1.7 GBP
Net profit, industry median (Chemicals - Specialty) 5.9 GBP
Out of every 100 GBP of revenue, 1.7 GBP is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 20.7 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.84%
- Paid out of profit
- 281%
You receive $0.03 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.